ELOVL1-IN-1 是一种 ELOVL1 抑制剂，详细信息请参考专利文献 WO2018107056A1 中的化合物 87。ELOVL1-IN-1 可以降低超长链脂肪酸的水平。ELOVL1-IN-1 可用于肾上腺脑白质营养不良 (ALD) 的研究。
货号:ajcx35790
CAS:2227482-41-7
分子式:C18H14F2N4O
分子量：340.33
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD)[1].

ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia[1].

ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐ ype (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)[1].

[1]. Charifson PS, et, al. 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels. WO2018107056A1.